Modafinil: Past, present and future

Expert Review of Neurotherapeutics

Volumn 2, Issue 4, 2002, Pages 449-457

  Ballas, Christos A ^a   Kim, Deborah ^a   Baldassano, Claudia F ^a   Hoeh, Nicholas ^a  

^a NONE   (United States)

Author keywords

Attention deficit hyperactivity disorder; Depression; Modafinil; Narcolepsy; Provigil; Sleep

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; DEXAMPHETAMINE; DOPAMINE; MODAFINIL; OREXIN; PSYCHOSTIMULANT AGENT; SEROTONIN;

ATTENTION DEFICIT DISORDER; BRAIN INJURY; DEPRESSION; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; FATIGUE; FOOD AND DRUG ADMINISTRATION; GABAERGIC SYSTEM; HUMAN; INTERNET; LEUKOPENIA; MEDLINE; MENTAL DISEASE; MULTIPLE SCLEROSIS; MYOTONIC DYSTROPHY; NARCOLEPSY; PARKINSON DISEASE; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; RECEPTOR BLOCKING; REVIEW; SEROTONINERGIC SYSTEM; SLEEP APNEA SYNDROME; SOMNOLENCE; SPONTANEOUS ABORTION;

EID: 0036308946     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.2.4.449     Document Type: Review

References (66)

1. Differential effects of a new central adrenergic agonist-modafinil- and d-amphetamine on sleep and early morning behaviour in young healthy volunteers
2. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers
3. Open-label, single-dose pharmacokinetic study of modafinil tablets: Influence of age and gender in nonnal subjects
4. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers
5. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil
6. Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers
7. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat
8. Hypothalamic arousal regions are activated during modafinil-induced wakefullness
9. The sleep switch: Hypothalamic control of sleep and wakefulness
10. Hypothalamic arousal regions are activated during modafinil-induced wakefullness
11. Dopaminergic role in stimulant-induced wakefulness
12. Modafinil does not affect serotonin efflux from rat frontal cortex synaptosomes: Comparison with known serotoninergic drugs
13. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism
14. Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice
15. Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: Comparison with amphetamine
16. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: Prevention by local GABAA receptor blockade
17. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus
18. Effect of modafinil on plasma melatonin, cortisol and growth hormone rhythms, rectal temperature and performance in healthy subjects during a 36 h sleep deprivation
19. Effect of modafinil on heat production and regulation of body temperatures in cold-exposed humans
20. Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals
21. Amplification of cortical serotonin release: A further neurochemical action of the vigilance-promoting drug modafinil
22. Standards of Practice Committee. Practice parameters for the treatment of narcolepsy: An update for 2000
23. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group
24. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group
25. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy
26. Use of modafinil in the treatment of narcoleps: A long term follow-up study
27. Long-term efficacy and safety of modafinil (PROVIGIL®) for the treatment of excessive daytime sleepiness associated with narcolepsy
28. Health-related quality of life effects of modafinil for treatment of narcolepsy
29. Narcolepsy in children: A practical guide to its diagnosis, treatment and follow-up
30. Problems associated with switch to modafinil - A novel alerting agent in narcolepsy
31. Interaction of modafinil and clomipramine as comedication in a narcoleptic patient
32. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil
33. Narcolepsy in children: A practical guide to its diagnosis, treatment and follow-up
34. A double-blind, placebo-controlled ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers
35. An evaluation of the abuse potential of modafinil using methylphenidate as a reference
36. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil
37. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group
38. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil
39. Use of modafinil in the treatment of narcolepsy: A long term follow-up study
40. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy
41. A double-blind, placebo-controlled investigation of the efficacy of modafinil for sustaining the alertness and performance of aviators: A helicopter simulator study
42. Modafinil, D-amphetamine and placebo during 64 hours of sustained mental work I. Effects on mood, fatigue, cognitive performance and body temperature
43. Naps and modafinil as countermeasures for the effects of sleep deprivation on cognitive performance
44. Efficacy and safety of modafinil (Provigil((R))) for the treatment of fatigue in multiple sclerosis: A two centre Phase 2 study
45. Modafinil for excessive daytime sleepiness in myotonic dystrophy
46. Antiparkinsonian and neuroprotective effects of modafanil in the MPTP-treated common marmoset
47. The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigrostriatal dopamine neurons in the male rat after a partial transection of the dopamine pathway
48. Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: An immunocytochemical and biochemical analysis
49. A stereological study on the neuroprotective actions of acute modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse
50. Modafinil prevents glutamate cytotoxicity in cultured cortical neurons
51. Modafinil for the treatment of excessive daytime sleepiness in Parkinson's disease: A case report
52. Effects of modafmil in children with attention-deficit/hyperactivity disorder: An open-label study
53. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea
54. Modafinil in obstructive sleep apnea-hypopnea syndrome: A pilot study in 6 patients
55. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome
56. Does short-term treatment with modafinil affect blood pressure in patients with obstructive sleep apnea?
57. Modafinil augmentation of antidepressant treatment in depression
58. Modafinil as an adjunctive agent in the treatment of fatigue and hypersomnia associated with major depression
59. Off-label uses of modafinil
60. Treatment of the alcoholic organic brain syndrome: Double-blind, placebo-controlled clinical, psychometric and electroencephalographic mapping studies with modafinil
61. On the treatment of the alcoholic organic brain syndrome with an alpha-adrenergic agonist modafinil: Double-blind, placebo-controlled clinical, psychometric and neurophysiological studies
62. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease
63. Psychostimulants for depression in hospitalized cancer patients
64. Methylphenidate andnortriptyline in the treatment of poststroke depression: A retrospective comparison
65. Psychostimulants in post-stroke depression